Artificial Intelligence (AI) in De Novo Drug Design Market

Source Domain: www.openpr.com

Market Growth and Future Projections: The AI-driven de novo drug design market has seen substantial growth from $1.9 billion in 2025 to an anticipated $8.07 billion by 2030, showing a compound annual growth rate (CAGR) of 33.7%. Factors such as technological advances, increased investments, and collaboration between stakeholders drive this growth.
Role of Artificial Intelligence: AI leverages machine learning and computational algorithms to efficiently create new molecular structures for specific biological targets, significantly improving the drug discovery process by reducing reliance on traditional, costly, and time-consuming methods.
Influence of Complex Diseases: The rise in the prevalence of complex and chronic diseases like diabetes, cardiovascular disorders, and cancers, due to genetic, environmental, and lifestyle factors, is a major growth driver. The need for innovative therapeutic solutions furthers the demand for AI in drug design.
Regional Market Dynamics: In 2025, North America dominated the AI for de novo drug design market, while the Asia-Pacific region is projected to experience the fastest growth rate in the coming years. The market is analyzed across various global regions to identify leadership and emerging opportunities.

You may have missed